<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6082936</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.01788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris&#x02014;Analysis of Four Different Ethnic Cohorts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Recke</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="fn001">*</xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/442877"/></contrib><contrib contrib-type="author"><name><surname>Konitzer</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lemcke</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Freitag</surname><given-names>Miriam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sommer</surname><given-names>Nele Maxi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abdelhady</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/559792"/></contrib><contrib contrib-type="author"><name><surname>Amoli</surname><given-names>Mahsa M.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Benoit</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>El-Chennawy</surname><given-names>Farha</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/592457"/></contrib><contrib contrib-type="author"><name><surname>Eldarouti</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eming</surname><given-names>R&#x000fc;diger</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gl&#x000e4;ser</surname><given-names>Regine</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;nther</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hadaschik</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Homey</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lieb</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff12"><sup>12</sup></xref><xref ref-type="aff" rid="aff13"><sup>13</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/529750"/></contrib><contrib contrib-type="author"><name><surname>Peitsch</surname><given-names>Wiebke K.</given-names></name><xref ref-type="aff" rid="aff14"><sup>14</sup></xref><xref ref-type="aff" rid="aff15"><sup>15</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pf&#x000f6;hler</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff16"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robati</surname><given-names>Reza M.</given-names></name><xref ref-type="aff" rid="aff17"><sup>17</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/559299"/></contrib><contrib contrib-type="author"><name><surname>Saeedi</surname><given-names>Marjan</given-names></name><xref ref-type="aff" rid="aff17"><sup>17</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/99267"/></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;rdy</surname><given-names>Mikl&#x000f3;s</given-names></name><xref ref-type="aff" rid="aff18"><sup>18</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sticherling</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff19"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uzun</surname><given-names>Soner</given-names></name><xref ref-type="aff" rid="aff20"><sup>20</sup></xref></contrib><contrib contrib-type="author"><name><surname>Worm</surname><given-names>Margitta</given-names></name><xref ref-type="aff" rid="aff21"><sup>21</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zillikens</surname><given-names>Detlef</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/467981"/></contrib><contrib contrib-type="author"><name><surname>Ibrahim</surname><given-names>Saleh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/534988"/></contrib><contrib contrib-type="author"><name><surname>Vidarsson</surname><given-names>Gestur</given-names></name><xref ref-type="aff" rid="aff22"><sup>22</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/88709"/></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Enno</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="fn001">*</xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/373973"/></contrib><contrib id="collab1" contrib-type="author"><collab>the German AIBD Genetic Study Group<contrib-group><contrib contrib-type="collab"><name><surname>Kreuter</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Zouboulis</surname><given-names>Christos C.</given-names></name></contrib><contrib contrib-type="collab"><name><surname>D&#x000e4;schlein</surname><given-names>Georg</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Steinbrink</surname><given-names>Kerstin</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Kunz</surname><given-names>Manfred</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Hunzelmann</surname><given-names>Nicolas</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Goetze</surname><given-names>Steven</given-names></name></contrib></contrib-group></collab><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>L&#x000fc;beck Institute of Experimental Dermatology (LIED), University of L&#x000fc;beck</institution>, <addr-line>L&#x000fc;beck</addr-line>, <country>Germany</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Dermatology, Allergology and Venereology, University of L&#x000fc;beck</institution>, <addr-line>L&#x000fc;beck</addr-line>, <country>Germany</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Dermatology, Faculty of Medicine, Cairo University</institution>, <addr-line>Giza</addr-line>, <country>Egypt</country></aff><aff id="aff4"><sup>4</sup><institution>Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular &#x02013; Cellular Sciences Institute, Tehran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Dermatology, Venereology and Allergology, University Hospital W&#x000fc;rzburg</institution>, <addr-line>W&#x000fc;rzburg</addr-line>, <country>Germany</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Clinical Pathology, Mansoura Faculty of Medicine, Mansoura University</institution>, <addr-line>Mansoura</addr-line>, <country>Egypt</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Dermatology and Allergology, Phillips-Universit&#x000e4;t Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country></aff><aff id="aff8"><sup>8</sup><institution>Department of Dermatology, Venereology and Allergology, Christian Albrecht University</institution>, <addr-line>Kiel</addr-line>, <country>Germany</country></aff><aff id="aff9"><sup>9</sup><institution>Department of Dermatology, University Hospital of Dresden</institution>, <addr-line>Dresden</addr-line>, <country>Germany</country></aff><aff id="aff10"><sup>10</sup><institution>Department of Dermatology, Ruprecht-Karls-University of Heidelberg</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country></aff><aff id="aff11"><sup>11</sup><institution>Department of Dermatology, Heinrich Heine University</institution>, <addr-line>D&#x000fc;sseldorf</addr-line>, <country>Germany</country></aff><aff id="aff12"><sup>12</sup><institution>Institute of Epidemiology, Christian-Albrechts-University</institution>, <addr-line>Kiel</addr-line>, <country>Germany</country></aff><aff id="aff13"><sup>13</sup><institution>Popgen Biobank, Christian-Albrechts-University</institution>, <addr-line>Kiel</addr-line>, <country>Germany</country></aff><aff id="aff14"><sup>14</sup><institution>Department of Dermatology, University Medical Center Mannheim, Heidelberg University</institution>, <addr-line>Mannheim</addr-line>, <country>Germany</country></aff><aff id="aff15"><sup>15</sup><institution>Department of Dermatology, Vivantes Klinikum im Friedrichshain</institution>, <addr-line>Berlin</addr-line>, <country>Germany</country></aff><aff id="aff16"><sup>16</sup><institution>Department of Dermatology, Saarland University Medical School</institution>, <addr-line>Homburg/Saar</addr-line>, <country>Germany</country></aff><aff id="aff17"><sup>17</sup><institution>Skin Research Center, Shahid Beheshti University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><aff id="aff18"><sup>18</sup><institution>Department of Dermatology, Ludwig Maximilian University Munich</institution>, <addr-line>Munich</addr-line>, <country>Germany</country></aff><aff id="aff19"><sup>19</sup><institution>Department of Dermatology, University of Erlangen-Nuremberg</institution>, <addr-line>Erlangen</addr-line>, <country>Germany</country></aff><aff id="aff20"><sup>20</sup><institution>Department of Dermatology, Faculty of Medicine, Akdeniz University</institution>, <addr-line>Antalya</addr-line>, <country>Turkey</country></aff><aff id="aff21"><sup>21</sup><institution>Department of Dermatology, Venerology and Allergology, Allergy Center Charit&#x000e9;, Charit&#x000e9;-Medical University Berlin</institution>, <addr-line>Berlin</addr-line>, <country>Germany</country></aff><aff id="aff22"><sup>22</sup><institution>Department of Experimental Hematology, Sanquin Research Institute</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Antony Basten, Garvan Institute of Medical Research, Australia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Paul Anthony Gleeson, University of Melbourne, Australia; Derry Charles Roopenian, Jackson Laboratory, United States</p></fn><corresp id="fn001">*Correspondence: Andreas Recke, <email>andreas.recke@uksh.de</email>; Enno Schmidt, <email>enno.schmidt@uksh.de</email></corresp><fn fn-type="other" id="fn002"><p><sup>&#x02020;</sup>A complete list of the members of German AIBD Genetic Study Group appears in the &#x0201c;The German AIBD Genetic Study group members.&#x0201d;</p></fn><fn fn-type="other" id="fn003"><p>Specialty section: This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>1788</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Recke, Konitzer, Lemcke, Freitag, Sommer, Abdelhady, Amoli, Benoit, El-Chennawy, Eldarouti, Eming, Gl&#x000e4;ser, G&#x000fc;nther, Hadaschik, Homey, Lieb, Peitsch, Pf&#x000f6;hler, Robati, Saeedi, S&#x000e1;rdy, Sticherling, Uzun, Worm, Zillikens, Ibrahim, Vidarsson, Schmidt and the German AIBD Genetic Study Group.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Recke, Konitzer, Lemcke, Freitag, Sommer, Abdelhady, Amoli, Benoit, El-Chennawy, Eldarouti, Eming, Gl&#x000e4;ser, G&#x000fc;nther, Hadaschik, Homey, Lieb, Peitsch, Pf&#x000f6;hler, Robati, Saeedi, S&#x000e1;rdy, Sticherling, Uzun, Worm, Zillikens, Ibrahim, Vidarsson, Schmidt and the German AIBD Genetic Study Group</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>IgG3 is the IgG subclass with the strongest effector functions among all four IgG subclasses and the highest degree of allelic variability among all constant immunoglobulin genes. Due to its genetic position, IgG3 is often the first isotype an antibody switches to before IgG1 or IgG4. Compared with the other IgG subclasses, it has a reduced half-life which is probably connected to a decreased affinity to the neonatal Fc receptor (FcRn). However, a few allelic variants harbor an amino acid replacement of His435 to Arg that reverts the half-life of the resulting IgG3 to the same level as the other IgG subclasses. Because of its functional impact, we hypothesized that the p.Arg435His variation could be associated with susceptibility to autoantibody-mediated diseases like pemphigus vulgaris (PV) and bullous pemphigoid (BP). Using a set of samples from German, Turkish, Egyptian, and Iranian patients and controls, we were able to demonstrate a genetic association of the p.Arg435His variation with PV risk, but not with BP risk. Our results suggest a hitherto unknown role for the function of IgG3 in the pathogenesis of PV.</p></abstract><kwd-group><kwd>immunology</kwd><kwd>dermatology</kwd><kwd>autoantibodies</kwd><kwd>allotype</kwd><kwd>pemphigus</kwd><kwd>pemphigoid</kwd><kwd>half-life</kwd><kwd>functional genetics</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><equation-count count="0"/><ref-count count="28"/><page-count count="8"/><word-count count="5872"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Of the four human IgG subclasses, IgG3 (gene IGHG3) exhibits the strongest capabilities to activate complement and effector cells of the innate immune system (<xref rid="B1" ref-type="bibr">1</xref>). Compared with the other IgG subclasses, IgG3 has a reduced half-life which is probably caused by a decreased affinity to FcRn (<xref rid="B2" ref-type="bibr">2</xref>). FcRn is involved in IgG transport across mucosal cells and the placenta. Moreover, FcRn is responsible for the exceptionally long half-life of IgG, and it rescues IgG from lysosomal degradation by recycling it back to the surface in endothelial cells. It further appears to be involved in IgG-mediated phagocytosis (<xref rid="B3" ref-type="bibr">3</xref>). The reduced half-life of IgG3 appears to be caused by an amino acid replacement at residue 435, where this IgG subclass typically carries an arginine instead of a histidine like the other IgG subclasses. From the 19 different alleles that the IMGT (ImMunoGeneTics information) database<xref ref-type="fn" rid="fn1"><sup>1</sup></xref> lists for IGHG3, 3 alleles contain a histidine instead of an arginine at this position (IgG3:p.Arg435His variation, NG_001019.5:g.1053927G&#x0003e;A, RefSNP rs4042056, Figure <xref ref-type="fig" rid="F1">1</xref>). These three alleles are associated with the G3m15 and G3m16 allotypes which are quite rare in the European population and more frequent in Asia and Africa (<xref rid="B4" ref-type="bibr">4</xref>). The histidine residue at position 435 leads to a higher affinity of IgG3 to FcRn and, consequently, to a prolonged half-life and most likely to an increased bioavailability in extravascular tissues (<xref rid="B2" ref-type="bibr">2</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Alignment of human IgG gene alleles. Alignment of all human IgG alleles listed in IMGT [<uri xlink:type="simple" xlink:href="http://www.imgt.org">http://www.imgt.org</uri> (Accessed: 15 March, 2015)], including GenBank accession number, gene names, isotype, allele numbering, and allotype numbering. Primer annealing sites for KASP and IgG3-specific PCR are shaded in blue, green, and red, respectively. Nucleotides unique in IgG3 (IgG3 specific) and the <underline>g.1053927G&#x0003e;A variation (p.Arg435His)</underline> are indicated with a red border. The full DNA sequence is shown for the reference sequence (AJ390235), for all other sequences, all bases except those that differ from the reference are masked by a dot. The amino acid sequence of the reference sequence is shown on the bottom site, together with the PCR fragment amplified for Sanger sequencing. The IGHG3 alleles that contain the <underline>g.1053927G&#x0003e;A</underline> variation are highlighted in pink (G3m15). A marker for DNA positions within the alignment set is given on the top scale.</p></caption><graphic xlink:href="fimmu-09-01788-g001"/></fig><p>Immunoglobulin allotypes represent serological features of genetic variations within the constant domains. Gm&#x02013;Am allotypes are inherited as fixed combination, also termed Gm&#x02013;Am haplotypes (<xref rid="B5" ref-type="bibr">5</xref>). They have been associated with various autoimmune diseases and different immune responses to bacterial infections (<xref rid="B6" ref-type="bibr">6</xref>). Of note, an association with immunoglobulin kappa light chain allotypes (Km allotypes) has been described for bullous pemphigoid (BP) but not for pemphigus vulgaris (PV) (<xref rid="B7" ref-type="bibr">7</xref>). However, the underlying mechanisms remain unexplained. Genetic polymorphisms with functional impact like the p.Arg435His variation of IgG3 might affect the etiology and pathogenesis of associated diseases, including autoantibody-mediated diseases. Therefore, this study was conducted to elucidate a possible association of the p.Arg435His variation with PV. PV is a severe autoimmune blistering disorder of the skin and surface-close mucous membranes, characterized by autoantibodies against desmosomal proteins of the epidermis and epithelia of mucosal membranes: desmoglein 3 and, in the mucocutaneous variant of PV, also desmoglein 1. IgG1 and IgG4, the most frequent IgG subclasses, have been demonstrated to cause acantholysis (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). IgG3, however, is often the first IgG subclass that appears immediately after the B cell switch from IgM (<xref rid="B10" ref-type="bibr">10</xref>). IgG anti-Dsg3 autoantibodies lead to steric hindrance in desmoglein interaction, altered cellular signaling, and aberrant cellular distribution of desmogleins resulting in acantholysis, the formation of flaccid blisters and erosions (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The events that lead to the irregular production of autoantibodies are largely unknown. While PV is known to be strongly associated with certain HLA alleles, such as DRB1*0402 and DQB1*0503, we have recently described an association with the first non-HLA gene, ST18, in PV patients from Egypt and Israel, but not from Germany (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Moreover, PV susceptibility was found to be associated with certain polymorphisms of Fc&#x003b3;RIIb and Fc&#x003b3;RIIc, indicating a role of peripheral tolerance in this disease (<xref rid="B15" ref-type="bibr">15</xref>). Here, we followed up on the idea of non-HLA susceptibility genes in pemphigus and investigated a possible association with the functionally important p.Arg435His variation of IgG3.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2-1"><title>Description of Cohorts</title><p>Samples and controls were stored and analyzed in the order in which they were collected, irrespective of age and gender. The inclusion criteria for PV and BP followed the recent guidelines of the German Society of Dermatology and European Academy of Dermatology and Venereology (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). In brief, PV was diagnosed based on the clinical picture with flaccid blisters and/or erosions on the skin and/or surface-close mucous membranes, intercellular IgG and/or C3 deposition in the epidermis/epithelia by direct immunofluorescence and/or detection of circulating anti-desmoglein 3 autoantibodies. In BP, diagnosis was made in patients with compatible clinical picture, i.e., tense blisters, erosions, prurigo-type lesions, and urticarial or eczematous lesions (<xref rid="B19" ref-type="bibr">19</xref>), deposition of IgG and/or C3 at the dermal&#x02013;epidermal junction by direct immunofluorescence microscopy, and/or detection of serum BP180 NC16A IgG. The respective diagnosis was re-evaluated in the Department of Dermatology, L&#x000fc;beck, Germany. Normal healthy controls were defined not to match any of the above criteria.</p></sec><sec id="S2-2"><title>Allotype-Specific ELISA</title><p>The G3m15 allotype was detected with a sandwich ELISA using the same single chain Fv (scFv) for capture and detection, as described (<xref rid="B2" ref-type="bibr">2</xref>). Briefly, microtiter plates (Nalge Nunc International, Rochester, NY, USA) were coated with anti-hIgG3 G3m15 scFv [1.5A10 anti G3m(s,t)] at 5&#x02009;&#x000b5;g/ml in carbonate buffer, pH 9.6. After washing with phosphate-buffered saline (PBS)/0.05% Tween-20 (PBST), plates were blocked with 1% biotin-free BSA (Carl Roth GmbH, Karlsruhe, Germany) in PBST (1% BSA in PBST). After washing, serum samples and the positive control G3m15 diluted in 1% BSA in PBST were loaded onto the plates and incubated for 2&#x02009;h. For detection, plates were incubated with biotin-conjugated anti-hIgG3 G3m15 scFv, diluted at 5&#x02009;&#x000b5;g/ml in 1% BSA in PBST, followed by peroxidase-conjugated streptavidin (Dako Deutschland GmbH, Hamburg, Germany) diluted 1:2,000 in 1% BSA in PBST. For colorimetric detection, plates were developed using TurboTMB (Perbio Science Deutschland GmbH, Bonn, Germany) and stopped with 1&#x02009;M H<sub>2</sub>SO<sub>4</sub> solution. OD values were measured at 450&#x02009;nm using a VICTOR 3&#x02122; reader (PerkinElmer Inc., Waltham, MA, USA).</p></sec><sec id="S2-3"><title>Determination of the rs4042056 Genotype by KASP Assay</title><p>The genotype of the rs4042056 was determined with the KASP method (LGC Genomics GmbH, Berlin, Germany), using a customized assay on a realplex<sup>2</sup> Mastercycler (Eppendorf AG, Hamburg, Germany), followed by fluorescence end-point reading with an Applied Biosystems 7800 Real-Time PCR system (Life Technologies GmbH, Darmstadt, Germany). For each sample, 10&#x02009;ng of genomic DNA was used and mixed with KASP reagents according to the manufacturer. The KASP assay contained the allele-specific HEX-conjugated primer 5&#x02032;-ggc tct tct gcg tga ag<underline>c</underline>-3&#x02032;, the FAM-conjugated primer 5&#x02032;-ggc tct tct gcg tga ag<underline>t</underline>-3&#x02032;, and the common primer 5&#x02032;-cag gtg gca gca ggg gaa ca-3&#x02032;.</p></sec><sec id="S2-4"><title>Amplification of the rs4042056 Flanking Sequence</title><p>The gene sequence flanking the rs4042056 in the human IgG3 gene was amplified by PCR using the forward primer 5&#x02032;-cag gtg gca gca ggg gaa ca-3&#x02032; and the reverse primer 5&#x02032;-cgg ccg tcg cac tca ttt ac-3&#x02032;, resulting in a 112&#x02009;bp product (Figure S1 in Supplementary Material). After agarose gel purification with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany), this product was subjected to Sanger sequencing at Eurofins Genomics, Ebersberg, Germany, using the same primers. For PCR, HotStart Phusion polymerase (Life Technologies GmbH, Darmstadt, Germany) was used with Phusion HiFidelity buffer, 1% DMSO and 10&#x02009;pmol of each primer. PCR program: 98&#x000b0;C for 30&#x02009;s; 10 cycles of 98&#x000b0;C for 5&#x02009;s, 75&#x000b0;C (&#x02212;1.0&#x000b0;C/cycle) for 20&#x02009;s, 72&#x000b0;C 10&#x02009;s; 25 cycles of 98&#x000b0;C for 5&#x02009;s, 65&#x000b0;C for 20&#x02009;s, 72&#x000b0;C 10&#x02009;s; final elongation for 5&#x02009;min at 72&#x000b0;C.</p></sec><sec id="S2-5"><title>Statistical Analysis</title><p>The open-source software GNU R version 3.15<xref ref-type="fn" rid="fn2"><sup>2</sup></xref> was used for statistical analysis, together with the package <italic>lme4</italic> for generalized linear mixed effects regression of co-dominant, recessive and dominant genetic effects, including stratification by ethnic cohort. For cohort-wise analyses, Lidstone additive smoothing was applied by addition of a pseudocount of &#x003b1;&#x02009;=&#x02009;0.5.</p><p>For combined analyses of serum and DNA samples, the generalized linear mixed effects regression was extended by using both sample type and ethnic cohort as stratification factors.</p><p>For comparison of genotyping results between different methods, Cohen&#x02019;s weighted kappa was calculated using the function <italic>cohen.kappa</italic> in package <italic>psych</italic>. Hardy&#x02013;Weinberg equilibrium was checked with the function <italic>HWAlltests</italic> from the R package <italic>HardyWeinberg</italic>.</p><p>To compare genotype frequencies determined in sera or DNA samples, we used a logistic regression with the risk allotype/allele as response variable and sample type (or genotyping method), ethnic origin and disease state (PV vs. healthy control) as covariates, including all two- and three-way interactions. For calculation of likelihood-ratio test <italic>p</italic> values, the function <italic>Anova</italic> from R package <italic>car</italic> was applied.</p></sec></sec><sec id="S3"><title>Results</title><p>We collected genomic DNA or serum samples from 516 PV patients and 555 population-matched healthy controls from Germany (<italic>n</italic>&#x02009;=&#x02009;137 patients, <italic>n</italic>&#x02009;=&#x02009;259 controls), Iran (<italic>n</italic>&#x02009;=&#x02009;78 patients, <italic>n</italic>&#x02009;=&#x02009;90 controls), Turkey (<italic>n</italic>&#x02009;=&#x02009;148 patients, <italic>n</italic>&#x02009;=&#x02009;19 controls), and Egypt (<italic>n</italic>&#x02009;=&#x02009;153 patients, 197 controls) (Table <xref rid="T1" ref-type="table">1</xref>). Furthermore, DNA or serum from 173 German patients with BP, another autoimmune blistering skin disease associated with autoantibodies against BP180 (collagen type XVII), was analyzed (Table <xref rid="T2" ref-type="table">2</xref>) (<xref rid="B20" ref-type="bibr">20</xref>). Separate cohorts were applied for serum and DNA samples.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>IgG3 rs4042056 variation in pemphigus vulgaris by KASP assay.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">KASP<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></th><th valign="top" align="center" colspan="4" rowspan="1">Cases</th><th valign="top" align="center" colspan="4" rowspan="1">Controls</th><th valign="top" align="center" colspan="2" rowspan="1">Recessive<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></th><th valign="top" align="center" colspan="2" rowspan="1">Dominant<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></th><th valign="top" align="center" colspan="2" rowspan="1">Co-dominant<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><hr/></th><th valign="top" align="center" colspan="4" rowspan="1"><hr/></th><th valign="top" align="center" colspan="4" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">rs4042056</th><th valign="top" align="center" rowspan="1" colspan="1">AA</th><th valign="top" align="center" rowspan="1" colspan="1">AG</th><th valign="top" align="center" rowspan="1" colspan="1">GG</th><th valign="top" align="center" rowspan="1" colspan="1">MAF (%)<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></th><th valign="top" align="center" rowspan="1" colspan="1">AA</th><th valign="top" align="center" rowspan="1" colspan="1">AG</th><th valign="top" align="center" rowspan="1" colspan="1">GG</th><th valign="top" align="center" rowspan="1" colspan="1">MAF (%)<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">83</td><td align="center" valign="top" rowspan="1" colspan="1">4.6*</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">180</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1">19 (1&#x02013;350)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0074</td><td align="center" valign="top" rowspan="1" colspan="1">5.2 (1&#x02013;27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.037</td><td align="center" valign="top" rowspan="1" colspan="1">3.2 (1.1&#x02013;9.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.6%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">95%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">0.55%</td><td align="center" valign="top" rowspan="1" colspan="1">99%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iran</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">7.1*</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">87</td><td align="center" valign="top" rowspan="1" colspan="1">3.3*</td><td align="center" valign="top" rowspan="1" colspan="1">1.9 (0.5&#x02013;7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">2.1 (0.6&#x02013;7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1">1.4 (0.7&#x02013;2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6.4%</td><td align="center" valign="top" rowspan="1" colspan="1">1.3%</td><td align="center" valign="top" rowspan="1" colspan="1">92%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.3%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">97%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Turkey</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">13*</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5.8 (0.33&#x02013;100)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12</td><td align="center" valign="top" rowspan="1" colspan="1">3.4 (0.4&#x02013;28)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">2.2 (0.6&#x02013;7.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">12%</td><td align="center" valign="top" rowspan="1" colspan="1">1.4%</td><td align="center" valign="top" rowspan="1" colspan="1">86%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">100%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Egypt</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">99</td><td align="center" valign="top" rowspan="1" colspan="1">2*</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">126</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">6.4 (0.3&#x02013;130)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">6.4 (0.3&#x02013;130)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">2.5 (0.6&#x02013;12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">98%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">100%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total<xref ref-type="table-fn" rid="tfn7"><sup>g</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">317</td><td align="center" valign="top" rowspan="1" colspan="1">6.2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">412</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td align="center" valign="top" rowspan="1" colspan="1">4.28 (1.6&#x02013;11.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0051</td><td align="center" valign="top" rowspan="1" colspan="1">3.7 (1.5&#x02013;9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0038</td><td align="center" valign="top" rowspan="1" colspan="1">2.78 (1.0&#x02013;7.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.9%</td><td align="center" valign="top" rowspan="1" colspan="1">0.6%</td><td align="center" valign="top" rowspan="1" colspan="1">94%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.7%</td><td align="center" valign="top" rowspan="1" colspan="1">0.2%</td><td align="center" valign="top" rowspan="1" colspan="1">99%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>ELISA<xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref></bold></td><td align="center" valign="top" colspan="4" rowspan="1"><bold>Cases</bold></td><td align="center" valign="top" colspan="4" rowspan="1"><bold>Controls</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1"><bold>Dominant<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>ELISA/KASP combined dominant<xref ref-type="table-fn" rid="tfn8"><sup>h</sup></xref></bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><hr/></td><td align="center" valign="top" colspan="4" rowspan="1"><hr/></td><td align="center" valign="top" colspan="4" rowspan="1"><hr/></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1"><hr/></td><td align="center" valign="top" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>G3m15</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Positive</bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>Negative</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>MAF (%)<xref ref-type="table-fn" rid="tfn5"><sup>e</sup></xref></bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Positive</bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>Negative</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>MAF (%)<xref ref-type="table-fn" rid="tfn5"><sup>e</sup></xref></bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold><italic>p</italic></bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold><italic>p</italic></bold></td></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>1</italic></td><td align="center" valign="top" colspan="2" rowspan="1"><italic>49</italic></td><td align="center" valign="top" rowspan="1" colspan="1"><italic>1.0</italic></td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" colspan="2" rowspan="1">77</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.6 (0.2&#x02013;15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>4.9 (0.9&#x02013;25.4)</italic></td><td align="center" valign="top" rowspan="1" colspan="1"><italic>0.061</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><italic>2.0%</italic></td><td align="center" valign="top" colspan="2" rowspan="1"><italic>98.0%</italic></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.3%</td><td align="center" valign="top" colspan="2" rowspan="1">98.7%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iran</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" colspan="2" rowspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" colspan="2" rowspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Turkey</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" colspan="2" rowspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" colspan="2" rowspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">n.a.<xref ref-type="table-fn" rid="tfn6"><sup>f</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td><td align="center" valign="top" rowspan="1" colspan="1">n.a.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.3%</td><td align="center" valign="top" colspan="2" rowspan="1">94.7%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Egypt</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" colspan="2" rowspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">1.9</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" colspan="2" rowspan="1">59</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.6 (0.33&#x02013;8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>2.5 (0.4&#x02013;13.7)</italic></td><td align="center" valign="top" rowspan="1" colspan="1"><italic>0.298</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.8%</td><td align="center" valign="top" colspan="2" rowspan="1">96.2%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.3%</td><td align="center" valign="top" colspan="2" rowspan="1">96.7%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total<xref ref-type="table-fn" rid="tfn7"><sup>g</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" colspan="2" rowspan="1">170</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>2</italic></td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" colspan="2" rowspan="1">136</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>1.1</italic></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.75 (0.4&#x02013;7.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">3.6 (1.5&#x02013;8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0041</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4%</td><td align="center" valign="top" colspan="2" rowspan="1">96%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.2%</td><td align="center" valign="top" colspan="2" rowspan="1">97.8%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic><sup>a</sup>The KASP assay directly determined the genotype of rs4042056 SNP that corresponds to the amino acid at residue 435. The minor A allele (g.1053927G&#x0003e;A) allele corresponds to p.Arg435His</italic>.</p></fn><fn id="tfn2"><p><italic><sup>b</sup>MAF, minor allele frequency, i.e., frequency of the A allele. An asterisk (*) indicates that the respective genotype distribution is not in Hardy&#x02013;Weinberg equilibrium</italic>.</p></fn><fn id="tfn3"><p><italic><sup>c</sup>Logistic regression (recessive, dominant, and co-dominant models) stratified by ethnic cohort. The 95% confidence interval is given for the odds ratio (OR); the <italic>p</italic> value (<italic>p</italic>) is given for the likelihood ratio test (LR test) on the genotype. For origin-wise models, the raw ORs are shown. In the combined analysis, a generalized linear mixed effects (with implicit adjustment) model with logit link function was applied. In case of 0 values in corresponding data, Lidstone additive smoothing was used to allow calculation of ORs and ensure convergence of the fitting routine</italic>.</p></fn><fn id="tfn4"><p><italic><sup>d</sup>The ELISA detects the G3m15 allotype of IgG3 that is linked to the p.Arg435His variation</italic>.</p></fn><fn id="tfn5"><p><italic><sup>e</sup>MAF, minor allele frequency, i.e., frequency of the allele encoding the G3m15 allotype, inferred assuming Hardy&#x02013;Weinberg equilibrium</italic>.</p></fn><fn id="tfn6"><p><italic><sup>f</sup>n.a., no serum samples available</italic>.</p></fn><fn id="tfn7"><p><italic><sup>g</sup>Regression calculated with a generalized linear mixed effects model (uncorrelated intercept and genotype effect as random effects)</italic>.</p></fn><fn id="tfn8"><p><italic><sup>h</sup>Logistic regression of combined ELISA and KASP results. The genotyping method was used for stratification in a random effects model (compare table footnote c). For the calculation across all ethnicities, ethnic origin was used together the genotyping method for stratification</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>IgG3 rs4042056 variation and G3m15 allotype in bullous pemphigoid.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">KASP<xref ref-type="table-fn" rid="tfn9"><sup>a</sup></xref></th><th valign="top" align="center" colspan="4" rowspan="1">Cases</th><th valign="top" align="center" colspan="4" rowspan="1">Controls</th><th valign="top" align="center" colspan="2" rowspan="1">Recessive<xref ref-type="table-fn" rid="tfn11"><sup>c</sup></xref></th><th valign="top" align="center" colspan="2" rowspan="1">Dominant<xref ref-type="table-fn" rid="tfn11"><sup>c</sup></xref></th><th valign="top" align="center" colspan="2" rowspan="1">Co-dominant<xref ref-type="table-fn" rid="tfn11"><sup>c</sup></xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><hr/></th><th valign="top" align="center" colspan="4" rowspan="1"><hr/></th><th valign="top" align="center" colspan="4" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th><th valign="top" align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">rs4042056</th><th valign="top" align="center" rowspan="1" colspan="1">AA</th><th valign="top" align="center" rowspan="1" colspan="1">AG</th><th valign="top" align="center" rowspan="1" colspan="1">GG</th><th valign="top" align="center" rowspan="1" colspan="1">MAF (%)<xref ref-type="table-fn" rid="tfn12"><sup>d</sup></xref></th><th valign="top" align="center" rowspan="1" colspan="1">AA</th><th valign="top" align="center" rowspan="1" colspan="1">AG</th><th valign="top" align="center" rowspan="1" colspan="1">GG</th><th valign="top" align="center" rowspan="1" colspan="1">MAF (%)<xref ref-type="table-fn" rid="tfn12"><sup>d</sup></xref></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">84</td><td align="center" valign="top" rowspan="1" colspan="1">0.58*</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">180</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">6.3 (0.3&#x02013;160)</td><td align="center" valign="top" rowspan="1" colspan="1">0.22</td><td align="center" valign="top" rowspan="1" colspan="1">3.2 (0.5&#x02013;20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 (0.7&#x02013;8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.2%</td><td align="center" valign="top" rowspan="1" colspan="1">1.2%</td><td align="center" valign="top" rowspan="1" colspan="1">97.8%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" rowspan="1" colspan="1">0.6%</td><td align="center" valign="top" rowspan="1" colspan="1">99.4%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>ELISA<xref ref-type="table-fn" rid="tfn10"><sup>b</sup></xref></bold></td><td align="center" valign="top" colspan="4" rowspan="1"><bold>Cases</bold></td><td align="center" valign="top" colspan="4" rowspan="1"><bold>Controls</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1"><bold>Dominant<xref ref-type="table-fn" rid="tfn11"><sup>c</sup></xref></bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>ELISA/KASP combined dominant<xref ref-type="table-fn" rid="tfn14"><sup>f</sup></xref></bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><hr/></td><td align="center" valign="top" colspan="4" rowspan="1"><hr/></td><td align="center" valign="top" colspan="4" rowspan="1"><hr/></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1"><hr/></td><td align="center" valign="top" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>G3m15</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Positive</bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>Negative</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>MAF (%)<xref ref-type="table-fn" rid="tfn13"><sup>e</sup></xref></bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>Positive</bold></td><td align="center" valign="top" colspan="2" rowspan="1"><bold>Negative</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>MAF (%)<xref ref-type="table-fn" rid="tfn13"><sup>e</sup></xref></bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold><italic>p</italic></bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold><italic>p</italic></bold></td></tr><tr><td align="center" valign="top" colspan="15" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>0</italic></td><td align="center" valign="top" colspan="2" rowspan="1"><italic>87</italic></td><td align="center" valign="top" rowspan="1" colspan="1"><italic>0.0</italic></td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" colspan="2" rowspan="1">77</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.3 (0.01&#x02013;7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 (0.2&#x02013;12.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0%</td><td align="center" valign="top" colspan="2" rowspan="1">100%</td><td align="center" valign="top" rowspan="1" colspan="1">1.3%</td><td align="center" valign="top" colspan="2" rowspan="1">98.7%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn9"><p><italic><sup>a</sup>Results from the KASP assay, respectively (for comparison of values and footnote comments see Table <xref rid="T1" ref-type="table">1</xref>)</italic>.</p></fn><fn id="tfn10"><p><italic><sup>b</sup>Results from the ELISA allotype determination (for comparison of values and footnote comments see Table <xref rid="T1" ref-type="table">1</xref>)</italic>.</p></fn><fn id="tfn11"><p><italic><sup>c</sup>Logistic regression (recessive, dominant, and co-dominant models) stratified by ethnic cohort. The 95% confidence interval is given for the odds ratio (OR); the <italic>p</italic> value (<italic>p</italic>) is given for the likelihood ratio test (LR test) on the genotype. In case of 0 values in corresponding data, Lidstone additive smoothing was used to allow calculation of ORs and ensure convergence of the fitting routine</italic>.</p></fn><fn id="tfn12"><p><italic><sup>d</sup>MAF, minor allele frequency, i.e., frequency of the A allele. An asterisk (*) indicates that the respective genotype distribution is not in Hardy&#x02013;Weinberg equilibrium</italic>.</p></fn><fn id="tfn13"><p><italic><sup>e</sup>MAF, minor allele frequency, i.e., frequency of the allele encoding the G3m15 allotype, inferred assuming Hardy&#x02013;Weinberg equilibrium</italic>.</p></fn><fn id="tfn14"><p><italic><sup>f</sup>Logistic regression of combined ELISA and KASP results. The genotyping method was used for stratification in a random effects model (compare table footnote h of Table <xref rid="T1" ref-type="table">1</xref>)</italic>.</p></fn></table-wrap-foot></table-wrap><p>Designing a PCR-based genotyping method for processing large sample numbers turned out to be challenging. The primer combination had to be specific for the IgG3 subclass and at the same time, should amplify most of the known allotypes and differentiate between the two allelic variants of the rs4042056 SNP (minor allele: g.1053927G&#x0003e;A, Figure <xref ref-type="fig" rid="F1">1</xref>). For this purpose, the <italic>Kompetitive Allele-Specific PCR</italic> method (KASP&#x02122;) appeared to be appropriate. The selectivity for the IgG3 gene is provided by a 3&#x02032; base (G/A) mismatch of the common primer with the sequence of IgG1, IgG2, and IgG4 gene. This mismatch also suppresses amplification in case of the IGHG3*03 allele [rs79545032, g.105769317A&#x0003e;G, minor allele frequency (MAF) 4% in and 16% in African populations (<xref rid="B21" ref-type="bibr">21</xref>)], but 17 of the 19 IgG3 gene alleles listed in the IMGT database were matching the primer sequence sufficiently. To verify the results of the KASP assay we amplified the region flanking the g.1053927G&#x0003e;A variation in the IgG3 gene by PCR in a small number of samples representing the different genotypes. The genotype of this SNP was determined using Sanger sequencing (Figure S1 in Supplementary Material). The comparison showed that both methods were correlating well [Table S1 in Supplementary Material, Cohen&#x02019;s weighted kappa&#x02009;=&#x02009;0.62 (95% CI: 0.39&#x02013;0.85), Fisher&#x02019;s exact test <italic>p</italic>&#x02009;=&#x02009;0.0054]. Furthermore, we used a fully saturated logistic regression model to evaluate the dependency of genotype frequencies on disease status, genotyping method, ethnic origin and all possible interactions between those. The likelihood ratio test revealed that only disease status (<italic>p</italic>&#x02009;=&#x02009;0.002) and ethnic origin (<italic>p</italic>&#x02009;=&#x02009;0.0095) show a significant influence on the genotype frequency, while the genotyping method&#x02014;and any interaction of genotyping method with the other covariates&#x02014;did not have an effect. This confirms that both genotyping methods are equivalent, and it indicates the frequency of the p.Arg435His variation is more common in MENA countries.</p><p>For serum samples (<italic>n</italic>&#x02009;=&#x02009;177 patients, <italic>n</italic>&#x02009;=&#x02009;136), we used a sandwich ELISA to serologically determine the G3m15 allotype that is described to be linked to the p.Arg435His variation (<xref rid="B2" ref-type="bibr">2</xref>) (Table <xref rid="T1" ref-type="table">1</xref>). The MAF estimation for the p.Arg435His variation did not differ significantly between the results from the KASP assay (3.3% in cases and 0.5% in controls) and the ELISA (2% in cases and 1.1% in controls). Moreover, the frequencies of the G3m15 allotype and the p.Arg435His variation were different in cases and controls especially in the Egyptian and the Turkish populations. The distribution of genotypes was not in Hardy&#x02013;Weinberg equilibrium for all cohorts of PV cases and in the Iranian cohort of controls.</p><p>To test if our finding for p.Arg435His variation in PV was a general phenomenon for all autoimmune blistering diseases (<xref rid="B20" ref-type="bibr">20</xref>) a cohort of <italic>n</italic>&#x02009;=&#x02009;173 German patients with BP was used. In this cohort of BP patients, no significant association of disease risk with the p.Arg435His or the G3m15 allotype was observed (Table <xref rid="T2" ref-type="table">2</xref>). The genotype distribution of BP cases had no Hardy-Weinberg equilibrium.</p></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>Allotypic variation has been associated with various autoimmune diseases including autoimmune blistering skin diseases (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). However, the functional role of allotypic variation is mostly unknown with the exception of the p.Arg435His variation which has been demonstrated to affect the half-life of IgG3 (<xref rid="B2" ref-type="bibr">2</xref>). We hypothesized that such a functionally relevant variation should be important for the susceptibility of autoantibody-mediated diseases like PV and BP.</p><p>High-throughput genotyping of the p.Arg435His variation is hampered by a high variability of the target gene region on the one hand, and a high degree of homology between IgG3 and the other three IgG subclass genes. We were able to design a genotyping method based on KASP technology, but this method did not discriminate heterozygotes from homozygotes. To check the results of this method in a subset of samples representing all detectable genotypes, we used PCR amplification and Sanger sequencing which overall confirmed the validity of the KASP assay. Using the KASP assay, we could demonstrate an association between the p.Arg435His variation and PV in the combined analyses of all ethnic groups, and within the group of German patients. Analysis within the other ethnic groups showed no significant association. This is most probably related to smaller cohort sizes, compared with the German one, because the odds ratio ranged between 1 and 3 in all ethnic cohorts.</p><p>As a secondary method for genotyping, we used an ELISA method that detects an amino acid variation which is, according to IMGT databases, linked to the p.Arg435His variation. Using this method alone, we could not find any association with PV disease, which might be explained by the overall lower number of available serum samples in the cohort. However, combining ELISA with KASP genotyping data, using genotyping method and ethnic origin for stratification in a mixed effects logistic regression analysis, reaffirmed the results gained by KASP assay alone. Furthermore, the genotype frequencies of cohorts did not differ significantly between the genotyping methods. Therefore, our results confirm that both genotyping by KASP assay and ELISA lead to equivalent results.</p><p>The IgG subclass of autoantibodies in PV is most frequently IgG4, followed by IgG1 (<xref rid="B9" ref-type="bibr">9</xref>). IgG2 and IgG3 are found in only sporadically. However, this does not exclude the possibility that the prolonged half-life of IgG3 with the p.Arg435His variation could affect very early preclinical stages of PV. IgG3 is the often first IgG subclass a B cell switches to from IgM, before IgG1 and IgG4 (<xref rid="B10" ref-type="bibr">10</xref>). Very early autoantibodies are possibly involved in feedback loops that self-promote autoimmune responses (<xref rid="B22" ref-type="bibr">22</xref>). In this scenario, the p.Arg435His variation might enhance these feedback loops by its ability to increase the half-life and biodistribution of these autoantibodies as well as the processing of IgG3-bound autoantigen by enhanced phagocytosis (<xref rid="B3" ref-type="bibr">3</xref>). We may speculate that the higher susceptibility to PV associated with the p.Arg435His variation is related to the altered promotion of preclinical PV to the clinically manifest disease. As an alternative explanation, the genomic region flanking the p.Arg435His variation might lead to a changed class switching behavior, as it has been shown for the G3m(b) (Figure <xref ref-type="fig" rid="F1">1</xref>, G3m5* allotype in current nomenclature) and G3m(g) (Figure <xref ref-type="fig" rid="F1">1</xref>, G3m21* allotype in current nomenclature) allotype (<xref rid="B23" ref-type="bibr">23</xref>). This alternative explanation assumes that the antibody repertoire is changed generally in way that promotes development of PV, but does not require the existence of early IgG3 autoantibodies.</p><p>In case of BP, other mechanisms might be important for the disease development. This is not only reflected by differences between PV and BP concerning associations with Fc&#x003b3;R polymorphisms (<xref rid="B15" ref-type="bibr">15</xref>), but also, as found here, concerning the p.Arg435His variation that does not appears to be associated with BP susceptibility.</p><p>A study with individuals from malaria-endemic regions in Benin showed that anti-malaria IgG3 is transferred from pregnant mothers with the p.Arg435His variation to their unborn children and that these children have an improved immunoprotection against malaria (<xref rid="B24" ref-type="bibr">24</xref>). In our cohorts, we could find an increased frequency of the minor g.1053927G&#x0003e;A (p.Arg435His) allele in the patient cohorts from Iran and Turkey, in contrast to Egypt and Germany. Iran and Turkey are denoted as malaria-endemic countries from the U.S. Centers of Disease Control, while Egypt and Germany are not (<xref rid="B25" ref-type="bibr">25</xref>). A connection between malaria and pemphigus diseases has not been described, yet. Malaria is transmitted by stinging insects. This is remarkable, because in endemic Pemphigus foliaceus in Brazil, a connection to stinging insects has been described: autoantibodies against desmoglein 1 from affected patients cross-react with a salivary protein of a biting fly (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). A genetic test does not allow to distinguish a direct effect of variation on susceptibility to a disease from a population effect. Our data show that the frequency of the p.Arg435His variation is higher in Iran and Turkey, favors the assumption of Dechavanne et al., that this variation could be an evolutionary adaption to malaria (<xref rid="B24" ref-type="bibr">24</xref>). Though highly speculative, a link between malaria and PV, be it genetic or environmental, would provide an alternative or additional explanation for the association between PV and the p.Arg435His variation: PV patients might preferably come from malaria-endemic areas within the investigated countries, while controls do not have this preference, leading to an increased frequency of the p.Arg435His variation. Such a population effect cannot be distinguished with the data available. However, a population effect would not imply any direct functional effect of the p.Arg435His variation on PV susceptibility or a theoretical involvement of IgG3 in PV.</p><p>The Hardy&#x02013;Weinberg equilibrium assumption did not hold in any of the PV case cohorts. Next to the above described technical challenges, population effects as described above and the known high degree of consanguinity in the investigated populations could explain this phenomenon (<xref rid="B28" ref-type="bibr">28</xref>).</p><p>In summary, we found an association of PV but not of BP with a genetic variation that is known to change half-life and effector functions of IgG3. These data suggest that IgG3 may play a role in the pathogenesis of PV or that there may be a link between malaria or malaria-transmitting mosquitoes and PV in MENA countries.</p></sec><sec id="S5"><title>The German AIBD Genetic Study Group Members</title><p><bold>Alexander Kreuter</bold>, Department of Dermatology, Venereology and Allergology, University of Bochum, Bochum, Germany (current affiliation: Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, Oberhausen, Germany); <bold>Christos C. Zouboulis</bold>, Department of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany; <bold>Georg D&#x000e4;schlein</bold>, Department of Dermatology, University of Greifswald, Greifswald, Germany; <bold>Kerstin Steinbrink</bold>, Department of Dermatology, University Medical Center Mainz, University of Mainz, Mainz, Germany; <bold>Manfred Kunz</bold>, Department of Dermatology, Venereology and Allergology, University of Leipzig, Leipzig, Germany; <bold>Nicolas Hunzelmann</bold>, Department of Dermatology, University of Cologne, Cologne, Germany; <bold>Steven Goetze</bold>, Department of Dermatology, University Hospital Jena, Jena, Germany.</p></sec><sec id="S6"><title>Ethics Statement</title><p>This study was carried out in accordance with the recommendations of institutional review board of the University of L&#x000fc;beck and the review boards of the collaborating centers. The protocol was approved by the institutional review board of the University of L&#x000fc;beck (File No. 08-156) and the review boards of the collaborating centers. All subjects gave written informed consent in accordance with the Declaration of Helsinki. Samples and demographic data of patients and controls were collected in adherence to ethics and German privacy protection regulations.</p></sec><sec id="S7"><title>Author Contributions</title><p>AR designed research, performed experiments, analyzed data, interpreted results, and wrote the manuscript; SK performed experiments, analyzed data, and wrote the manuscript; SL interpreted results and wrote the manuscript; MF performed experiments and analyzed data; NS, MA, SB, FE-C, ME, RE, RG, CG, EH, BH, WL, WP, RR, MSaeedi, MS&#x000e1;rdy, MSticherling, SU, MW, and DZ recruited patients and organized sample collections; SI designed research, interpreted results, and wrote the manuscript; GV designed research, interpreted results, and wrote the manuscript; ES recruited patients, interpreted results, and wrote the manuscript; the German AIBD Genetic Study Group organized sample collections.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We thank everybody involved in the collection of blood samples and all volunteers and patients who donated blood for this study. This work received infrastructural support from the Deutsche Forschungsgemeinschaft Cluster of Excellence Inflammation at Interfaces (Cluster 306/2).</p></ack><fn-group><fn id="fn1"><p><sup>1</sup><uri xlink:type="simple" xlink:href="http://www.imgt.org">http://www.imgt.org</uri> (Accessed: 25 January, 2017).</p></fn><fn id="fn2"><p><sup>2</sup><uri xlink:type="simple" xlink:href="http://www.R-project.org/">http://www.R-project.org/</uri> (Accessed: 27 February, 2018).</p></fn></fn-group><sec id="S10" sec-type="supplementary-material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at <uri xlink:type="simple" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.01788/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2018.01788/full#supplementary-material</uri>.</p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Image_1.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Sitaru</surname><given-names>C</given-names></name><name><surname>Vidarsson</surname><given-names>G</given-names></name><name><surname>Evensen</surname><given-names>M</given-names></name><name><surname>Chiriac</surname><given-names>MT</given-names></name><name><surname>Ludwig</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation</article-title>. <source>J Autoimmun</source> (<year>2010</year>) <volume>34</volume>:<fpage>435</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2009.11.003</pub-id><?supplied-pmid 19948391?><pub-id pub-id-type="pmid">19948391</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>NM</given-names></name><name><surname>Andersen</surname><given-names>JT</given-names></name><name><surname>Stemerding</surname><given-names>AM</given-names></name><name><surname>Bjarnarson</surname><given-names>SP</given-names></name><name><surname>Verheul</surname><given-names>RC</given-names></name><name><surname>Gerritsen</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential</article-title>. <source>Nat Commun</source> (<year>2011</year>) <volume>2</volume>:<fpage>599</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms1608</pub-id><?supplied-pmid 22186895?><pub-id pub-id-type="pmid">22186895</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>NM</given-names></name><name><surname>Einarsd&#x000f3;ttir</surname><given-names>HK</given-names></name><name><surname>Stemerding</surname><given-names>AM</given-names></name><name><surname>Vidarsson</surname><given-names>G</given-names></name></person-group>. <article-title>The multiple facets of FcRn in immunity</article-title>. <source>Immunol Rev</source> (<year>2015</year>) <volume>268</volume>:<fpage>253</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1111/imr.12331</pub-id><?supplied-pmid 26497526?><pub-id pub-id-type="pmid">26497526</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefranc</surname><given-names>G</given-names></name><name><surname>Chaabani</surname><given-names>H</given-names></name><name><surname>Van Loghem</surname><given-names>E</given-names></name><name><surname>Lefranc</surname><given-names>MP</given-names></name><name><surname>De Lange</surname><given-names>G</given-names></name><name><surname>Helal</surname><given-names>AN</given-names></name></person-group>. <article-title>Simultaneous absence of the human IgG1, IgG2, IgG4 and IgA1 subclasses: immunological and immunogenetical considerations</article-title>. <source>Eur J Immunol</source> (<year>1983</year>) <volume>13</volume>:<fpage>240</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830130312</pub-id><?supplied-pmid 6832214?><pub-id pub-id-type="pmid">6832214</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefranc</surname><given-names>M-P</given-names></name><name><surname>Lefranc</surname><given-names>G</given-names></name></person-group>. <article-title>Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism</article-title>. <source>Methods Mol Biol</source> (<year>2012</year>) <volume>882</volume>:<fpage>635</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1007/978-1-61779-842-9_34</pub-id><?supplied-pmid 22665258?><pub-id pub-id-type="pmid">22665258</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pressler</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>JP</given-names></name><name><surname>Espersen</surname><given-names>F</given-names></name><name><surname>Pedersen</surname><given-names>SS</given-names></name><name><surname>Fomsgaard</surname><given-names>A</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Immunoglobulin allotypes and IgG subclass antibody response to <italic>Pseudomonas aeruginosa</italic> antigens in chronically infected cystic fibrosis patients</article-title>. <source>Clin Exp Immunol</source> (<year>1992</year>) <volume>90</volume>:<fpage>209</fpage>&#x02013;<lpage>14</lpage>.<?supplied-pmid 1424275?><pub-id pub-id-type="pmid">1424275</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitouni</surname><given-names>M</given-names></name><name><surname>Martel</surname><given-names>P</given-names></name><name><surname>Ben Ayed</surname><given-names>M</given-names></name><name><surname>Raux</surname><given-names>G</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Joly</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Pemphigus is not associated with allotypic markers of immunoglobulin kappa</article-title>. <source>Genes Immun</source> (<year>2002</year>) <volume>3</volume>:<fpage>50</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1038/sj.gene.6363817</pub-id><?supplied-pmid 11857063?><pub-id pub-id-type="pmid">11857063</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funakoshi</surname><given-names>T</given-names></name><name><surname>Lunardon</surname><given-names>L</given-names></name><name><surname>Ellebrecht</surname><given-names>CT</given-names></name><name><surname>Nagler</surname><given-names>AR</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>CE</given-names></name><name><surname>Payne</surname><given-names>AS</given-names></name></person-group>. <article-title>Enrichment of total serum IgG4 in patients with pemphigus</article-title>. <source>Br J Dermatol</source> (<year>2012</year>) <volume>167</volume>:<fpage>1245</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.11144.x</pub-id><?supplied-pmid 22803659?><pub-id pub-id-type="pmid">22803659</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futei</surname><given-names>Y</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kuroda-Kinoshita</surname><given-names>K</given-names></name><name><surname>Ohya</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name></person-group>. <article-title>Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus</article-title>. <source>J Dermatol Sci</source> (<year>2001</year>) <volume>26</volume>:<fpage>55</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/S0923-1811(00)00158-4</pub-id><?supplied-pmid 11323221?><pub-id pub-id-type="pmid">11323221</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>KJL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Collins</surname><given-names>AM</given-names></name></person-group>. <article-title>Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels</article-title>. <source>Immunol Cell Biol</source> (<year>2014</year>) <volume>92</volume>:<fpage>729</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1038/icb.2014.44</pub-id><?supplied-pmid 24913324?><pub-id pub-id-type="pmid">24913324</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>JR</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name></person-group>
<article-title>Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome</article-title>. <source>N Engl J Med</source> (<year>2006</year>) <volume>355</volume>:<fpage>1800</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMra061111</pub-id><pub-id pub-id-type="pmid">17065642</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasperkiewicz</surname><given-names>M</given-names></name><name><surname>Ellebrecht</surname><given-names>CT</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Yamagami</surname><given-names>J</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Payne</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>Pemphigus</article-title>. <source>Nat Rev Dis Primers</source> (<year>2017</year>) <volume>3</volume>:<fpage>17026</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.26</pub-id><pub-id pub-id-type="pmid">28492232</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarig</surname><given-names>O</given-names></name><name><surname>Bercovici</surname><given-names>S</given-names></name><name><surname>Zoller</surname><given-names>L</given-names></name><name><surname>Goldberg</surname><given-names>I</given-names></name><name><surname>Indelman</surname><given-names>M</given-names></name><name><surname>Nahum</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris</article-title>. <source>J Invest Dermatol</source> (<year>2012</year>) <volume>132</volume>:<fpage>1798</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="doi">10.1038/jid.2012.46</pub-id><?supplied-pmid 22437316?><pub-id pub-id-type="pmid">22437316</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>AA</given-names></name><name><surname>Brautbar</surname><given-names>C</given-names></name><name><surname>Szafer</surname><given-names>F</given-names></name><name><surname>Friedmann</surname><given-names>A</given-names></name><name><surname>Tzfoni</surname><given-names>E</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>A newly characterized HLA DQ beta allele associated with pemphigus vulgaris</article-title>. <source>Science</source> (<year>1988</year>) <volume>239</volume>:<fpage>1026</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1126/science.2894075</pub-id><?supplied-pmid 2894075?><pub-id pub-id-type="pmid">2894075</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Vidarsson</surname><given-names>G</given-names></name><name><surname>Ludwig</surname><given-names>RJ</given-names></name><name><surname>Freitag</surname><given-names>M</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>S</given-names></name><name><surname>Vonthein</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Allelic and copy-number variations of Fc&#x003b3;Rs affect granulocyte function and susceptibility for autoimmune blistering diseases</article-title>. <source>J Autoimmun</source> (<year>2015</year>) <volume>61</volume>:<fpage>36</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2015.05.004</pub-id><pub-id pub-id-type="pmid">26032265</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feliciani</surname><given-names>C</given-names></name><name><surname>Joly</surname><given-names>P</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name><name><surname>Zambruno</surname><given-names>G</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Ioannides</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology</article-title>. <source>Br J Dermatol</source> (<year>2015</year>) <volume>172</volume>:<fpage>867</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1111/bjd.13717</pub-id><?supplied-pmid 25827742?><pub-id pub-id-type="pmid">25827742</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertl</surname><given-names>M</given-names></name><name><surname>Jedlickova</surname><given-names>H</given-names></name><name><surname>Karpati</surname><given-names>S</given-names></name><name><surname>Marinovic</surname><given-names>B</given-names></name><name><surname>Uzun</surname><given-names>S</given-names></name><name><surname>Yayli</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Pemphigus. S2 guideline for diagnosis and treatment &#x02013; guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)</article-title>. <source>J Eur Acad Dermatol Venereol</source> (<year>2015</year>) <volume>29</volume>:<fpage>405</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1111/jdv.12772</pub-id><pub-id pub-id-type="pmid">25338479</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Hertl</surname><given-names>M</given-names></name><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name><name><surname>Sitaru</surname><given-names>C</given-names></name><name><surname>Eming</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid</article-title>. <source>J Dtsch Dermatol Ges</source> (<year>2015</year>) <volume>13</volume>:<fpage>713</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1111/ddg.12612</pub-id><pub-id pub-id-type="pmid">26110729</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>della Torre</surname><given-names>R</given-names></name><name><surname>Borradori</surname><given-names>L</given-names></name></person-group>. <article-title>Clinical features and practical diagnosis of bullous pemphigoid</article-title>. <source>Dermatol Clin</source> (<year>2011</year>) <volume>29</volume>:<fpage>427</fpage>&#x02013;<lpage>438</lpage>,viii&#x02013;ix.<pub-id pub-id-type="doi">10.1016/j.det.2011.03.010</pub-id><?supplied-pmid 21605808?><pub-id pub-id-type="pmid">21605808</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Pemphigoid diseases</article-title>. <source>Lancet</source> (<year>2013</year>) <volume>381</volume>:<fpage>320</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61140-4</pub-id><?supplied-pmid 23237497?><pub-id pub-id-type="pmid">23237497</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Fairley</surname><given-names>S</given-names></name><name><surname>Zheng-Bradley</surname><given-names>X</given-names></name><name><surname>Streeter</surname><given-names>I</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Lowy</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>The international Genome sample resource (IGSR): a worldwide collection of genome variation incorporating the 1000 Genomes Project data</article-title>. <source>Nucleic Acids Res</source> (<year>2017</year>) <volume>45</volume>:<fpage>D854</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkw829</pub-id><?supplied-pmid 27638885?><pub-id pub-id-type="pmid">27638885</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hjelm</surname><given-names>F</given-names></name><name><surname>Carlsson</surname><given-names>F</given-names></name><name><surname>Getahun</surname><given-names>A</given-names></name><name><surname>Heyman</surname><given-names>B</given-names></name></person-group>
<article-title>Antibody-mediated regulation of the immune response</article-title>. <source>Scand J Immunol</source> (<year>2006</year>) <volume>64</volume>:<fpage>177</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-3083.2006.01818.x</pub-id><pub-id pub-id-type="pmid">16918684</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Rabbani</surname><given-names>H</given-names></name><name><surname>Mills</surname><given-names>FC</given-names></name><name><surname>Severinson</surname><given-names>E</given-names></name><name><surname>Hammarstr&#x000f6;m</surname><given-names>L</given-names></name></person-group>. <article-title>Allotype-associated variation in the human gamma3 switch region as a basis for differences in IgG3 production</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>158</volume>:<fpage>5849</fpage>&#x02013;<lpage>59</lpage>.<?supplied-pmid 9190937?><pub-id pub-id-type="pmid">9190937</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dechavanne</surname><given-names>C</given-names></name><name><surname>Dechavanne</surname><given-names>S</given-names></name><name><surname>Sadissou</surname><given-names>I</given-names></name><name><surname>Lokossou</surname><given-names>AG</given-names></name><name><surname>Alvarado</surname><given-names>F</given-names></name><name><surname>Dambrun</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against <italic>Plasmodium falciparum</italic> malaria during infancy: a birth cohort study in Benin</article-title>. <source>PLoS Med</source> (<year>2017</year>) <volume>14</volume>:<fpage>e1002403</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pmed.1002403</pub-id><?supplied-pmid 28991911?><pub-id pub-id-type="pmid">28991911</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brunette</surname><given-names>GW</given-names></name><collab>Centers for Disease Control (U.S.)</collab></person-group>
<source>CDC Yellow Book 2018: Health Information for International Travel</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name> (<year>2017</year>).</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>V</given-names></name><name><surname>Millikan</surname><given-names>RC</given-names></name><name><surname>Rivitti</surname><given-names>EA</given-names></name><name><surname>Hans-Filho</surname><given-names>G</given-names></name><name><surname>Eaton</surname><given-names>DP</given-names></name><name><surname>Warren</surname><given-names>SJP</given-names></name><etal/></person-group>
<article-title>Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem)</article-title>. <source>J Investig Dermatol Symp Proc</source> (<year>2004</year>) <volume>9</volume>:<fpage>34</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1111/j.1087-0024.2004.00833.x</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Jeong</surname><given-names>JS</given-names></name><name><surname>Maldonado</surname><given-names>M</given-names></name><name><surname>Valenzuela</surname><given-names>JG</given-names></name><name><surname>Gomes</surname><given-names>R</given-names></name><name><surname>Teixeira</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>189</volume>:<fpage>1535</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1200842</pub-id><?supplied-pmid 22798673?><pub-id pub-id-type="pmid">22798673</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbouche</surname><given-names>M-R</given-names></name><name><surname>Mekki</surname><given-names>N</given-names></name><name><surname>Ben-Ali</surname><given-names>M</given-names></name><name><surname>Ben-Mustapha</surname><given-names>I</given-names></name></person-group>. <article-title>Lessons from genetic studies of primary immunodeficiencies in a highly consanguineous population</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>737</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.00737</pub-id><?supplied-pmid 28702026?><pub-id pub-id-type="pmid">28702026</pub-id></mixed-citation></ref></ref-list></back></article>